ARCH Venture Management, LLC
In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 17, 2026), ARCH Venture Management, LLC reported 9 stock positions worth $651.7 million. Its top holding was Maze Therapeutics (MAZE) at 26.2% of the portfolio, followed by Beam Therapeutics (BEAM, 19.3%) and Rapport Therapeutics (RAPP, 17.4%). Compared with Q3 2025, it opened 1 new position and sold out of 1. The biggest buy was a new position in 10X Genomics Class A (TXG) and the biggest sale an exit from Cero Therapeutics Holdings I (CERO).
- Most Recent 13F
- Q2 2026
- Location
- CHICAGO, IL
- CIK
- 0001274403
- Portfolio Value
- $651.7M (Q4 2025)
- SEC Filing
- 0001012975-26-000153 ↗ filed Feb 17, 2026
Holdings Value
Holdings 9 stocks · $651.7M
| MAZE Maze Therapeutics Inc. | 26.19% | 4,120,053 | $170.7M | No change |
| BEAM Beam Therapeutics Inc. | 19.31% | 4,540,132 | $125.9M | No change |
| RAPP Rapport Therapeutics Inc. | 17.36% | 3,728,738 | $113.1M | No change |
| LYEL Lyell Immunopharma Inc. | 13.03% | 2,759,072 | $84.9M | No change |
| VIR Vir Biotechnology Inc. | 11.95% | 12,916,663 | $77.9M | No change |
| ERAS Erasca Inc. | 6.31% | 11,055,554 | $41.1M | No change |
| GOSS Gossamer Bio Inc. | 3.83% | 8,055,916 | $25.0M | No change |
| TXG 10X Genomics Inc. Class A | 1.85% | 737,539 | $12.0M | New |
| QTTB Q32 Bio Inc. | 0.16% | 320,482 | $1.1M | No change |
Portfolio Sells Q3 2025 → Q4 2025
| CERO Cero Therapeutics Holdings I | Sold out | 0.00% | −0.02 |
Portfolio Buys Q3 2025 → Q4 2025
| TXG 10X Genomics Inc. Class A | New | 1.85% | +1.85 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 12 | $1.1B | PBLS, BEAM, RAPP, SPTX, ERAS |
| Q1 2026 | 10 | $677.1M | MAZE, RAPP, VIR, ERAS, BEAM |
| Q4 2025 | 9 | $651.7M | MAZE, BEAM, RAPP, LYEL, VIR |
| Q3 2025 | 9 | $492.4M | RAPP, BEAM, MAZE, VIR, LYEL |
| Q2 2025 | 11 | $299.1M | BEAM, VIR, MAZE, RAPP, VERV |
| Q1 2025 | 9 | $206.2M | BEAM, MAZE, RAPP, ERAS, VERV |
| Q4 2024 | 9 | $230.2M | BEAM, RAPP, ERAS, VERV, GOSS |
| Q3 2024 | 9 | $260.6M | BEAM, RAPP, ERAS, QTTB, VERV |
| Q2 2024 | 9 | $266.0M | BEAM, RAPP, ERAS, VERV, GOSS |
| Q1 2024 | 8 | $80.3M | VERV, ERAS, GOSS, DNLI, QTTB |